Glioblastoma Multiforme Market Size Forecasted To Achieve 3.69 Billion By 2029 With Steady Growth

"We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Glioblastoma Multiforme Market Size and Projected Growth Rate?
The market size of glioblastoma multiforme has significantly expanded over the past years. It's projected to scale up from $2.50 billion in 2024 to $2.71 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%. The previous growth can be traced back to the escalating cases of glioblastoma multiforme, advancements in healthcare facilities, heightened level of awareness, improved access to sophisticated therapies, and an increase in the aging populace.

Over the next few years, the market size for glioblastoma multiforme is expected to experience robust growth, reaching $3.69 billion in 2029 with an 8.1% compound annual growth rate (CAGR). This expected surge during the forecast period is likely due to a rise in brain and other nervous system cancer diagnoses, a growing openness towards surgical procedures, improved awareness and early disease detection, and an increase in research and development activities. Upcoming trends for this period include medical technology advancements, improvements in imaging techniques, personalized medicine, AI implementation in diagnoses, and progress in technology and science.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21191

What Are the Major Segments in the Glioblastoma Multiforme Market?
The glioblastoma multiforme market covered in this report is segmented -

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools
3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types
4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:
1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites
2) By Temozolomide: Branded (Temodar), Generic Temozolomide
3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine), Generic Lomustine
5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp

What Are The Driving Glioblastoma Multiforme Market Evolution?
The expected increase in cases of brain disorders is projected to propel the glioblastoma multiforme market in the future. Brain disorders, which disrupt the brain's structure or function leading to cognitive, emotional, or physical impairments, are on the rise due to factors such as an aging society, extended lifespan, lifestyle conditions, and enhanced diagnostic abilities. Comprehensive understanding of these disorders aids in the research progression of glioblastoma multiforme (GBM), resulting in better early diagnosis, innovative treatments, and improved patient prognosis. Research into these neurological diseases enables scientists to identify genetic and molecular connections responsible for GBM development. As an example, Dementia Australia reported in February 2025 that about 433,300 Australians currently live with dementia, a figure that is predicted to grow to 812,500 by 2054. Additionally, younger-onset dementia is affecting around 29,000 people in 2025, and this number is anticipated to rise to 41,000 by 2054. Therefore, the growing brain disorder instances will fuel the expansion of the glioblastoma multiforme market.

Which Firms Dominate The Glioblastoma Multiforme Market Segments?
Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

What Are the Latest Developing Trends in the Glioblastoma Multiforme Market?
Leading corporations in the glioblastoma multiforme market are concentrating their resources on the development of innovative treatments like CAR T-cell therapies to meet the pressing medical demands of this severe type of cancer. The principle behind CAR T-cell treatment is the alteration of a patient's T-cells to more efficiently target and eliminate cancer cells. For instance, Chimeric Therapeutics Limited, a biotech firm based in Australia, initiated a Phase IB clinical trial for its CHM 1101 (CLXT CAR T) therapy in June 2023. This therapy is designed for patients with recurrent or progressive glioblastoma multiforme (GBM). With the trial carried out in various centers, the goal is to assess the safety and effectiveness of this treatment, as well as to set the appropriate dosage for Phase 2. The Phase 1a trial demonstrated disease stability, providing a foundation for further development through this ongoing trial. The company anticipates that the results will guide the design of a registration trial and aid in soliciting regulatory feedback.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Which Is The Largest Region In The Glioblastoma Multiforme Market?
North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Glioblastoma Multiforme Market?
2. What is the CAGR expected in the Glioblastoma Multiforme Market?
3. What Are the Key Innovations Transforming the Glioblastoma Multiforme Industry?
4. Which Region Is Leading the Glioblastoma Multiforme Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments."

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.